Share Name |
Share Symbol |
Market |
Type |
Share ISIN |
Share Description |
Futura Medical Plc |
LSE:FUM |
London |
Ordinary Share |
GB0033278473 |
ORD 0.2P |
|
Price Change |
% Change |
Share Price |
Bid Price |
Offer Price |
High Price |
Low Price |
Open Price |
Shares Traded |
Last Trade |
|
-0.70 |
-4.61% |
14.50 |
14.00 |
15.00 |
15.25 |
14.50 |
15.25 |
207,264 |
13:01:06 |
Industry Sector |
Turnover (m) |
Profit (m) |
EPS - Basic |
PE Ratio |
Market Cap (m) |
Pharmaceuticals & Biotechnology |
0.0 |
-11.1 |
-4.4 |
- |
36 |
Futura Medical Share Discussion Threads

Showing 16851 to 16875 of 19725 messages
Date | Subject | Author | Discuss |
---|
10/6/2019 15:43 | 'management' is not Futura's forte ! |  mikethebike4 | |
10/6/2019 15:21 | Many bags, over time, I am holding for a few years initially.
In the short term a break through 28p will be significant and opens up a larger move to 40’s
Good to see some press coverage
Still under the radar, good chance to get in early. Reminds me when I was the only one on the (STX) thread accumulating in late 20’s & 30’s, now 110p+ I have been doing the same with (MSYS), on the pull back to 1p, just have to dyor and trust these Companies have solid management to deliver going fwd GL |  ny boy | |
10/6/2019 15:19 | Multibagger staring us in the face.
The market size is massive. |  j777j | |
10/6/2019 15:00 | That article reads like scripted PR. |  glavey | |
10/6/2019 14:23 | Futura Medical PLC (LON:FUM) saw its shares shoot higher on Monday after ‘house’ broker Liberum Capital highlighted an article published in ‘The Guardian’ newspaper which could spark interest in the group’s main product.
In a note to clients, the City broker’s analysts pointed out that over the weekend the newspaper published an in-depth piece on the emerging treatments for erectile dysfunction (ED) with a significant focus on the AIM-listed firm’s MED2005 which is in a P3 study due to read-out by the end of the year.
They said: “The article highlights the lack of clinical advances in ED over the past 20 years and the emerging opportunity for products that can address the shortcomings of the PDe-5 inhibitor class (Viagra) with MED2005 appearing to offer convenience and side-effect profile benefits.”
The analysts concluded: “This will help to drive interest in what appears to be a very over-looked product in terms of its potential to address a very large market |  j777j | |
10/6/2019 10:39 | How many bags do you see here going forward? |  j777j | |
10/6/2019 07:31 | Yep, it’s why we are invested for the long term, should bounce nicely off support here, buy with confidence imo but dyor |  ny boy | |
10/6/2019 07:24 | Even if Futura only gets 20% of that,a 15% royalty is still $54 million a year.Amazing potential. |  j777j | |
10/6/2019 06:38 | "Within three months of its launch, Viagra had already earned Pfizer $400m, and over the past two decades, it has consistently generated annual sales to the tune of $1.8bn." |  j777j | |
09/6/2019 09:24 | From 1989, using patches: hTTps://www.karger.com/Article/Abstract/281528 |  rrr | |
09/6/2019 09:23 | Interesting how far back this idea goes - this from 1990 uses a paste:
hTTps://www.ncbi.nlm.nih.gov/pubmed/2107336?dopt=Abstract |  rrr | |
09/6/2019 08:32 | Great article kd, many thanks. |  rrr | |
09/6/2019 06:45 | guardian webiste- The race to replace Viagra
https://www.theguardian.com/science/2019/jun/09/race-to-replace-viagra-patents-erectile-dysfunction-drug-medical-research-cialis-eroxon |  keifer derrin | |
07/6/2019 12:29 | Im still in hear quite heavily and comfortable with it. Trying not to look too often as it will be a bit of a slow burn until later in the year with fee mm shenanagans in between. |  ragnarr | |
07/6/2019 12:20 | Buyers back in !! |  dickiebird2 | |
07/6/2019 11:20 | certainly 'bottom testing' ! |  mikethebike4 | |
06/6/2019 15:20 | Testing the bottom of the up trend channel, if it holds, it should do well from here. |  ny boy | |
06/6/2019 14:25 | I expect some dip buying over the next week or so, before a break to new highs |  ny boy | |
06/6/2019 14:11 | Everyone sold out ?
I guess no long term investors left then lol!
(MSYS) is the next big thing imo but dyor! |  ny boy | |
29/5/2019 10:24 | Anyone joining the MAIS shareholder action group? |  kemche | |
29/5/2019 09:52 | LO selling again Good luck ... placing coming |  ayesha4 | |
24/5/2019 11:11 | You are not wrong there
Global Erectile Dysfunction Drugs Market Will Reach USD 7.10 Billion by 2024: Zion Market Research
According to the report, global erectile dysfunction drugs market was valued at approximately USD 4.82 billion in 2017 and is expected to generate revenue of around USD 7.10 billion by end of 2024, growing at a CAGR of around 5.70% between 2018 and 2024. |  ragnarr | |
24/5/2019 09:51 | Not surprising when you consider the upside. |  j777j | |
24/5/2019 09:40 | some quite hefty buys today - 50k, 100k, 250k - somebody must be taking an interest |  mikethebike4 | |
23/5/2019 15:10 | Ahead of the rerating one hopes. |  j777j | |